OTC Watch

All stocks / ZEOX

Zeo ScientifiX, Inc. ZEOX

Zeo ScientifiX (ZEOX): a late 10-K notice in September 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated floatLate filing OTCQBFlorida, USA
Live quote on OTC Markets

Market listing

Full name
ZEO SCIENTIFIX INC.
Market tier
OTCQB
Trading status
Active
Last trade
Nov 16
Source: Stockwatch, 2026-11-17

News headlines

ZEO ScientifiX Makes Industry History as First Facility to Achieve AABB's Newly Established Quality Management Systems Certification
2026-11-03 07:00 · News Release
Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine
2026-10-26 07:00 · News Release
ZEO ScientifiX Plans Expansion into Georgia and Tennessee as New Regenerative Medicine Laws Take Effect
2026-09-15 07:00 · News Release
ZEO ScientifiX Announces Multidisciplinary Expert Faculty Lineup for the ZEO Xperience
2026-09-01 07:00 · News Release
ZEO ScientifiX Launches First-of-Its-Kind ZEO Xperience, a Three-Day Immersive Regenerative Medicine Experience for Healthcare Professionals
2026-08-04 07:00 · News Release
ZEO ScientifiX Strengthens South Florida's Growing Biotechnology Ecosystem Through Regenerative Medicine Innovation
2026-07-21 07:00 · News Release
ZEO ScientifiX Reports Strong Revenue Growth for Three Months and Six Months Ended April 30, 2026
2026-07-08 07:00 · News Release
ZEO ScientifiX to Host Live Educational Webinar for Healthcare Professionals Exploring the Southeast Regenerative Medicine Revolution
2026-07-01 07:00 · News Release
ZEO ScientifiX Donates Products to Support Pediatric Burn Reconstruction Mission in Peru
2026-06-16 07:00 · News Release
ZEO ScientifiX Expands Medical Advisory Board with Leaders in Regenerative and Longevity Medicine
2026-06-09 07:00 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-10-31
The report says
Revenue
$5,199,000
Net loss
($5,521,000)
What it means

It spends more than it earns

Under strain

Customers paid it $5.2 million in the year. It lost $5.5 million. For every $1 that came in, about $2.06 went out.

The report says
Cash and cash equivalents
$221,000
Net cash used in operating activities
($718,000)
What it means

The cash could run out soon

Under strain

It had $221,000 in the bank and used about $59,833 a month. At that pace the money lasts about 4 months unless it borrows or sells more shares.

The report says
Total assets
$1,527,000
Total liabilities
$2,950,000
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $1.5 million. Its debts and unpaid bills add up to $3 million. That is about $1.93 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-13

Estimated float about 5,919,326 shares as of 2026-11-13: 7,837,441 outstanding minus 1,918,115 held by 3 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Late filing2026-09-28

Filed NT 10-K on 2026-09-28: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Late filing2026-09-14

Filed NT 10-Q on 2026-09-14: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Shares outstanding

Source: SEC filings
2026-01-31
7.6M
2026-03-16
7.8M
2026-04-30
7.8M
2026-06-12
7.8M
2026-06-30
7.8M
2026-09-30
7.8M
2026-10-12
7.8M
2026-11-13
7.8M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 10-Q10-Q
2026-11-03 8-K8-K
2026-10-30 8-K8-K
2026-10-26 8-K8-K
2026-10-13 10-KT10-KT
2026-09-28 NT 10-KNT 10-K
2026-09-15 8-K8-K
2026-09-15 8-K8-K
2026-09-14 NT 10-QNT 10-Q
2026-09-01 8-K8-K
2026-08-04 8-K8-K
2026-07-24 S-8S-8

Common questions about ZEOX

Does ZEOX file reports with the SEC?

Yes. Zeo ScientifiX files with the SEC under company number 0001557376. The most recent filing we hold is a 10-Q dated 2026-11-16.

Source record

How many ZEOX shares are outstanding?

7,837,441 shares as of 2026-11-13, as reported to the SEC.

Source record

Has ZEOX filed reports late?

Yes. In the last 12 months it filed 2 late-filing notices, most recently a NT 10-K on 2026-09-28. A notice means a report was not ready on time; check whether the report followed.

Source record

Who runs Zeo ScientifiX?

Officers named in its insider filings: Ian T Bothwell (CEO & CFO), John David Kisiday (Chief Science Officer) and George Craig Shapiro (Chief Medical Officer).

Source record

Is Zeo ScientifiX making money?

Customers paid it $5.2 million in the year. It lost $5.5 million. For every $1 that came in, about $2.06 went out. (Annual figures to 2025-10-31. Facts from the company's own report, not a recommendation.)

Source record